HomeCompareCLBS vs ADC

CLBS vs ADC: Dividend Comparison 2026

CLBS yields 131.33% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLBS wins by $12.81M in total portfolio value
10 years
CLBS
CLBS
● Live price
131.33%
Share price
$0.43
Annual div
$0.56
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.99M
Annual income
$5,201,713.69
Full CLBS calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — CLBS vs ADC

📍 CLBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLBSADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLBS + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLBS pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLBS
Annual income on $10K today (after 15% tax)
$11,163.23/yr
After 10yr DRIP, annual income (after tax)
$4,421,456.64/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, CLBS beats the other by $4,352,778.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLBS + ADC for your $10,000?

CLBS: 50%ADC: 50%
100% ADC50/50100% CLBS
Portfolio after 10yr
$6.59M
Annual income
$2,641,255.49/yr
Blended yield
40.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

CLBS
No analyst data
Altman Z
-42.9
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLBS buys
0
ADC buys
0
No recent congressional trades found for CLBS or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLBSADC
Forward yield131.33%4.13%
Annual dividend / share$0.56$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$12.99M$178.9K
Annual income after 10y$5,201,713.69$80,797.29
Total dividends collected$11.90M$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: CLBS vs ADC ($10,000, DRIP)

YearCLBS PortfolioCLBS Income/yrADC PortfolioADC Income/yrGap
1← crossover$23,833$13,133.21$10,990$580.36+$12.8KCLBS
2$54,754$29,252.94$12,301$860.26+$42.5KCLBS
3$121,396$62,809.15$14,104$1,298.62+$107.3KCLBS
4$260,039$130,144.39$16,691$2,008.16+$243.3KCLBS
5$538,781$260,539.45$20,580$3,205.09+$518.2KCLBS
6$1,080,999$504,503.28$26,754$5,330.02+$1.05MCLBS
7$2,102,673$946,004.75$37,196$9,345.14+$2.07MCLBS
8$3,969,574$1,719,713.85$56,244$17,523.09+$3.91MCLBS
9$7,281,647$3,034,202.37$94,286$35,736.21+$7.19MCLBS
10$12,993,076$5,201,713.69$178,949$80,797.29+$12.81MCLBS

CLBS vs ADC: Complete Analysis 2026

CLBSStock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Full CLBS Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this CLBS vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLBS vs SCHDCLBS vs JEPICLBS vs OCLBS vs KOCLBS vs MAINCLBS vs NNNCLBS vs EPRTCLBS vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.